GenMark Diagnostics, Inc. (NASDAQ:GNMK) has scheduled a conference call for 28th October 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.genmarkdx.com
Earnings Expectation
GenMark Diagnostics, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 28th October 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.06 per share from revenue of $ 39.26 million. Looking ahead, the full year loss are expected at $ 0.26 per share on the revenues of $ 164.19 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 42.60 million ~ $ 42.60 million
Full Year 2020 topline are forecasted in a range of$ 155.00 million ~ $ 165.00 million
Click Here For More Historical Outlooks Of GenMark Diagnostics, Inc.
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges.
